Terry Rosen—alum, donor, commencement speaker and serial biotech entrepreneur—has launched another successful start up.
Soon after selling Flexus Biosciences for $1.25 billion, Rosen co-founded Arcus Biosciences in 2015 to bring to market new therapies based on immuno-oncology. This rapidly expanding field harnesses the immune system to fight cancer.
Rosen's new startup, based in Hayward, has already raised about $120 million and seeks to place two potential products in clinical trials in 2017.
Rosen, a member of the research group of Clayton Heathcock, graduated in 1985 with a chemistry Ph.D. He has been a generous donor and an active alum. Last May, Rosen gave the 2016 commencement address in Zellerbach Hall.